health economic models

1. Early models
1. Calculate the economically justifiable price (EJP) based on a hypothetical profile of the intervention
2. Global cost-effectiveness models and budget impact models
1. The team members of Th(is)²Modeling have a proven track record (see bibliography) of developing Core models for headquarters. These models were later used for reimbursement purposes in different countries
2. Th(is)²Modeling conducts the literature searches to populate the models with the latest available evidence, including performing indirect comparisons
3. When needed, we investigate real-world data to populate the models
3. Roll-out affiliate and country adaptations
1. Alignment and mediation between headquarters and local affiliates needs
2. Adaptation of global core models to local settings
3. Training local affiliates on adapting and using global core models
4. Drug or intervention formulary tools
1. In some countries hospitals decide on whether an intervention is adopted or not. This calls for specific, easy-to-understand tools that can be presented by the local sales team.

Check the bibliography for some examples on the peer-reviewed published Disease Models developed by the team (Hypertension, COPD, obesity, cardiovascular disease, renal disease)

quality Assurance and expert opinion

We are experienced in performing quality checks and quality assurance of health economic models. This can also be combined with reviewing the associated reports, publications, global value dossiers, and submission dossiers developed by other teams. We conduct a cell-by-cell evaluation, face validity, internal and external validation following the latest scientific standards (CHEERS, ISPOR, Drummond…etc).

Given our broad experience in HTA dossiers and modeling in cardiovascular, metabolic (diabetes, obesity), renal and respiratory disease, we are also offering expert opinion on the dossiers you are working on.

Value Communication

1. Technical reports
2. HTA submission dossiers
3. Conference abstracts and presentation
4. Peer reviewed manuscripts
5. Global value dossiers
6. Training

trainings

Th(is)²Modeling is very experienced in providing training to different target audiences adapted to their prior knowledge of HEOR. Some of the trainings we deliver include (but are not limited to):

1. Introductory course in health economics
2. Introductory courses in health economics modeling
3. Use of TreeAge to build health economic models
4. How to use and adapt specific models, built by ourselves or built by others (roll out of global models).
5. Training on models/tools that are used to get a product on a hospital formulary.
6. Training on the Core Diabetes Model: As we led the Core Diabetes Model for many years, Th(is)²Modeling is best placed to provide training on the use of this model

Delphi Panels and Advisory-Boards

Input from Experts is key to validate model concepts and ensure that conclusions produced are robust. The team has conducted an extensive number of advisory boards with key opinion leaders supported by the team`s medical background to ask the right questions.

The team at Th(is)²Modeling has performed and published several Delphi panel studies. The keys to success are selecting the most appropriate experts and developing an easy to complete questionnaire that minimizes uncertainty. Our publications on Delphi panels can be found in our bibliography page.

clinical trials

Obtaining reimbursement is never easy, and is even more complex when clinical trials do not anticipate requirements of HTA agencies. Th(is)²Modeling combines the medical and health economic knowledge to advise on the needs of HTA agencies for clinical trials. This ensures trials are proactively designed in an optimal manner to capture endpoints that drive the value proposition of medical technology. We can support with:

1. Protocol adaptations: to meet economic/HTA agency guidelines. In addition to collecting resource use and quality of life data for piggy-back analyses or to populate models
2. Review protocols and (e)CRFs
3. Support the strategic design of clinical trials to assure the necessary data is collected from a health economic perspective for reimbursement dossiers
4. Set up of pragmatic prospective observational studies with a focus on the collection of health economic model parameters (e.g. quality of life data and resource use utilization)

real world evidence

With the expansion of real-world data such as electronic medical records, these real-world sources are often used to inform health economic models. This allows actual patterns in medical practice to be reflected, thus using the best evidence to support the market access strategies.